Results 21 to 30 of about 3,471,294 (187)

Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping [PDF]

Microbiology Spectrum
Ceftazidime-avibactam and cefiderocol represent two of the few alternatives for infections by KPC-producing Enterobacterales. We reported the emergence of resistance to both ceftazidime-avibactam and cefiderocol in a KPC-producing ST131-Escherichia coli (
Juan Antonio Castillo-Polo, Marta Hernández-García, Ainhize Maruri-Aransolo, Carmen de la Vega, Patricia Ruiz-Garbajosa, Rafael Cantón   +5 more
doaj   +3 more sources

Addressing antimicrobial resistance: Structural insights into cefiderocol’s mode of action and emerging resistance mechanisms

Journal of Infection and Public Health
Cefiderocol represents a significant advancement in the treatment of multidrug-resistant Gram-negative bacterial infections. Its unique uptake mechanism, leveraging bacterial iron transport pathways for membrane permeation, sets it apart from ...
Mohd Zulkifli Salleh
doaj   +5 more sources

The solution to drug resistance of Gram-negative bacteria – Cefiderocol

Journal of Education, Health and Sport, 2023
Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
Magdalena Kołodziej, Kamila Gorczyca, Ilona Jastrzębska, Paweł Węgorowski, Michał Wieczorek   +4 more
doaj   +3 more sources

Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing Enterobacterales: Insights from Comparative Genomics. [PDF]

Antibiotics (Basel)
Background/Objectives: Cefiderocol is a novel siderophore cephalosporin with potent in vitro activity against a broad spectrum of Gram-negative bacteria, including carbapenemase-producing Enterobacterales (CPE).
Tristancho-Baró A, López-Calleja AI, Milagro A, Ariza M, Viñeta V, Fortuño B, López C, Latorre-Millán M, Clusa L, Badenas-Alzugaray D, Martínez R, Torres C, Rezusta A.   +12 more
europepmc   +2 more sources

Spontaneous Emergence of Cefiderocol Resistance in <i>Klebsiella pneumoniae</i> KPC-163: Genomic and Transcriptomic Insights. [PDF]

Antibiotics (Basel)
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an urgent public health threat due to its rapid dissemination and resistance to last-line antibiotics.
Luu I, Mezcord V, Escalante J, Traglia GM, Tuttobene MR, Rodriguez C, Cheng CF, Valle Q, Sharma R, Tolmasky ME, Bonomo RA, Rao G, Pasteran F, Ramirez MS.   +13 more
europepmc   +2 more sources

Cefiderocol Resistance Conferred by Plasmid-Located Ferric Citrate Transport System in KPC-Producing Klebsiella pneumoniae. [PDF]

Emerg Infect Dis
Cefiderocol (FDC), a siderophore-cephalosporin conjugate, is the newest option for treating infection with carbapenem-resistant gram-negative bacteria. We identified a novel mechanism contributing to decreased FDC susceptibility in Klebsiella pneumoniae ...
Polani R, De Francesco A, Tomolillo D, Artuso I, Equestre M, Trirocco R, Arcari G, Antonelli G, Villa L, Prosseda G, Visca P, Carattoli A.   +11 more
europepmc   +2 more sources

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. [PDF]

Antimicrob Agents Chemother, 2023
Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in the chromosomal cephalosporinase (PDC) along with
Teran N, Egge SL, Phe K, Baptista RP, Tam VH, Miller WR.   +5 more
europepmc   +2 more sources

Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors. [PDF]

Sci Rep
Cefiderocol (CFDC), a novel siderophore-cephalosporin, is effective against multidrug-resistant (MDR) pathogens, but the emergence of resistance threatens its future use in treating infections.
Al-Marzooq F, Ahli H, Aldhaheri R, Aleissaee O, Alzaabi A, Alsaadi A, Almansoori H, Ghazawi A, Daoud L, Ahmad A, Collyns T.   +10 more
europepmc   +2 more sources

Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol [PDF]

Scientific Reports
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option.
Sidonie Hanna, Kevin La, Yutaka Yoshii, Maud Gits-Muselli, Imane El Meouche, Yasmine Benhadid-brahmi, Stéphane Bonacorsi, André Birgy   +7 more
doaj   +2 more sources

Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates. [PDF]

Eur J Clin Microbiol Infect Dis
A series of NDM-producing Escherichia coli ST167 clinical isolates exhibiting resistance to cefiderocol (FDC), with no previous exposure to this antibiotic, were analyzed in this study. The antimicrobial susceptibility testing and phenotypic detection of
Sadek M, Duran JB, Chakraborty T, Poirel L, NARA Network, Nordmann P.   +5 more
europepmc   +2 more sources